Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers September 21, 2017
Pharmacy Choice - News - Front Page Healthcare News - September 21, 2017

Pharmacy News

 Front Page Healthcare News
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/21/17 - "Method for Preparing Palbociclib" in Patent Application Approval Process (USPTO 20170247379)
By a News Reporter-Staff News Editor at Women's Health Weekly A patent application by the inventor XU, Xuenong, filed on May 15, 2017, was made available online on September 7, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. The following quote was obtained by the news editors from the background inf
9/21/17 - 18 Stocks Moving In Thursday's Pre-Market Session
Gainers Calgon Carbon Corporation rose 62.1 percent to $21.40 in pre-market trading after the company agreed to be acquired by Kuraray at $21.50 per share in cash. BioCryst Pharmaceuticals, Inc. shares rose 12 percent to $5.90 in the pre-market trading session after the company disclosed that its RAPIVAB received the FDA approval for a pediatric...
9/21/17 - 5 Stocks To Watch For September 21, 2017
Herman Miller shares slipped 2.72 percent to $34.00 in the after-hours trading session. Wall Street expects Manchester United PLC to report quarterly earnings at $7.88 per share on revenue of $205.85 million before the opening bell. Manchester United shares declined 0.58 percent to $17.10 in after-hours trading. Amphastar Pharmaceuticals Inc report
9/21/17 - ACA repeal would pain state [The Dominion Post, Morgantown, W.Va.]
Sept. 21 The latest Republican effort to repeal the Affordable Care Act would cut $2 billion of health care funding for West Virginia. s John D. Rockefeller IV School of Policy& Politics, said the legislation proposed by GOP senators Lindsey Graham, of South Carolina, and Bill Cassidy, of Louisiana, to repeal the ACA would roll back the Medicaid
9/21/17 - Academy of Nutrition and Dietetics Opposes Amended House Health Care Bill
The Academy of Nutrition and Dietetics issued the following news release:. The Academy of Nutrition and Dietetics, the world's largest organization of food and nutrition professionals, urges the U.S. Senate to reject the American Health Care Act of 2017 as amended by the Graham-Cassidy proposal. "The Academy urges the Senate and House of Represent
9/21/17 - Adult Cardiovascular Surgical Instrument Package Market Dynamics, Comprehensive Analysis, Business Growth, Prospects and Opportunities 2024
ReportsMonitor.comhasaddedanewreporttoitsdatabase 2017-2022 Adult Cardiovascular Surgical Instrument Package Report on Global and United States Market, Status and Forecas...
9/21/17 - Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Files An 8-K Regulation FD Disclosure
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Files An 8-K Regulation FD DisclosureItem 7.01. Regulation FD Disclosure. On September20, 2017, Aerie Pharmaceuticals, Inc. (the Company) issued a press release announcing that a meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee of the U.S. Food and Drug Administration has been sched
9/21/17 - Africa Medical Devices Market to Reach a Valuation of USD 7069.61 Million by 2023
Africa Medical Devices Market Information, by Product type, by Therapeutic Application and by End User- Forecast to 2023 Pune, India 09/21/2017 Market Research Future adds new report of "Africa Medical Devices Market Research Report- Forecast to 2023" it contains Company information, geographical data and Table of ContentCompetitive Analysis:
9/21/17 - AHCA Suspends the License of the Rehabilitation Center of Hollywood Hills
The Florida Agency for Health Care Administration issued the following news release:. Today, the Agency for Health Care Administration issued an emergency suspension order on the license of the Rehabilitation Center of Hollywood Hills. Per the AHCA investigation's initial findings, residents of the facility did not receive timely medical care becau
9/21/17 - Akari Therapeutics Announces Regulatory Progress Following FDA Meeting
Akari Therapeutics, a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases, announces that, following advice from a recent FDA Type B End of Phase II Meeting, it plans to advance its lead investigational drug, Coversin?, towards Phase III clini
9/21/17 - Alliance for Retired Americans Issues Statement on Latest GOP Attempt at Health Plan
The Alliance for Retired Americans issued the following statement by Executive Director Richard Fiesta regarding the Graham-Cassidy bill to repeal the Affordable Care Act. "We're outraged that this bill is the first step in ending Medicaid as we know it," said Richard Fiesta, executive director of the Alliance for Retired Americans. "Congress sho
9/21/17 - Alligator Bioscience to Present ADC-1013 Intratumoral Clinical Phase I Study Results at SITC in November 2017
Alligator Bioscience, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today that results from a clinical phase I study of the drug candidate ADC-1013 will be presented at the Society for Immunotherapy of Cancer 32nd Annual Meeting, held from 8-12 November 2017 at the Gaylord National..
9/21/17 - Alnylam achieves breakthrough RNAi success as PhIII patisiran study hits all goals, shares soar [Tehran Times (Iran)]
The big Cambridge, MA- based biotech says that their Phase III study of patisiran partnered with Sanofi scored a positive hit for the primary as well as all secondary endpoints in treating rare cases of hereditary ATTR amyloidosis with polyneuropathy. The score sets up Alnylams first new drug application with the FDA before the end of this year wit
9/21/17 - Altimmune Announces its Phase 2 Flu Vaccine Trial with NasoVAX Open for Enrollment [Syrian Arab News Agency]
Altimmune, Inc., a clinical-stage immunotherapeutics company, today announced that they have been cleared by the FDA to initiate their Phase 2 clinical study of NasoVAX, the Companys intranasally administered recombinant flu vaccine. NasoVAX is a new type of influenza vaccine that uses intranasal administration to potentially stimulate a broader an
9/21/17 - AMICUS THERAPEUTICS INC FILES (8-K) Disclosing Other Events, Financial Statements and Exhibits
On September 21, 2017, Amicus Therapeutics, Inc. issued a press release announcing that the U.S. FDA granted Orphan Drug Designation for ATB200/AT2221 for Pompe Disease. A copy of this press release is attached hereto as Exhibit 99.1. Description 99.1 Press Release dated September 21, 2017 titled " U.S. FDA Grants Orphan Drug Designation for ATB200
9/21/17 - AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Other Events
AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Other EventsItem 8.01. Other Events. On September21, 2017, Amicus Therapeutics,Inc. (the Company) issued a press release announcing that the U.S. FDA granted Orphan Drug Designation for ATB200/AT2221 for Pompe Disease. A copy of this press release is attached hereto as Exhibit99.1. Item 9.01
9/21/17 - AMRI Assembles a Comprehensive Medical Device Expert Solutions Team
In response to evolving industry guidelines, AMRI has assembled a comprehensive medical device solutions team to help customers navigate the regulatory complexities of developing and testing medical device products. With expertise in biocompatibility, microbiology, toxicology, extractables/leachables, device functionality,...
9/21/17 - Another Attempt to Cut Insurance
Another Attempt to Cut Insurance. Senate Republicans, this time through the Graham-Cassidy proposal, are trying again to repeal the Affordable Care Act. This bill would eliminate 12 percent of the funding of the Centers for Disease Control and Prevention.
9/21/17 - argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX-113 in immune thrombocytopenia [Sport360]
Breda, the Netherlands/ Ghent, Belgium- argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that it has recruited 50% of the immune thrombocytopenia patients in the Phase 2 proof-of-concept study of ARGX-113.
9/21/17 - ASN and Advocates From 21 Other Health Care Organizations are on Capitol Hill Urging Congress to Support Kidney Disease Research and the Living Donor Protection Act
They will urge Congress to continue its historic support of research funding for the National Institutes of Health and to cosponsor and pass the Living Donor Protection Act, no-cost legislation to eliminate barriers to living donation and increase access to transplants. therapies coupled with a national organ shortage, we need Congress to move.
9/21/17 - Assured Bites, Inc. Petition Approval Marks First-Ever FDA Qualified Health Claim Linking Early Peanut Introduction to Allergy Prevention
By a News Reporter-Staff News Editor at Politics& Government Business Assured Bites, Inc., a New York- based family health and wellness company on the forefront of peanut allergy prevention, is pleased to announce the U.S Food and Drug Administration has approved its petition for a qualified health claim linking early peanut introduction and the
9/21/17 - Audentes Therapeutics Announces Dosing of First Patient in ASPIRO, a Phase 1/2 Clinical Trial of AT132 for the Treatment of X-Linked Myotubular Myopathy
Audentes Therapeutics, Inc., a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced it has commenced dosing of patients in ASPIRO, a Phase 1/ 2 clinical trial of AT132 for the treatment of X-Linked Myotubular Myopathy. ASPIRO is a mu
9/21/17 - AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Pompe Disease
AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the expansion of its pipeline to Pompe disease. This pre-clinical program becomes AVROBIO s third gene therapy for Lysosomal Storage Disorders, following on the heels of the Company s Phase 1 Fabry p
9/21/17 - Bad health care bill, again
Postpone tax reform and everything else for a while longer because the Senate is going to try to repeal and replace the Affordable Care Act one more time before September ends and while it can do it with the votes of only 50 senators. If it happens, this vote will be particularly meaningful for Arkansas and its two senators, because the Graham-Cass
9/21/17 - Bellus Medical Receives Seven Prestigious Industry Awards [T-break Tech (Middle East)]
Congratulations to Bellus Medical President and CEO Joe Proctor for his outstanding work in leading the effort to elevate the microneedling industry with breakthrough technology thats backed by quality and safety. These accolades follow Bellus Medicals recent market expansion after receiving the Medical Device License from Health Canada to...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement